Name | beta.-Cyclodextrin, sulfobutyl ethers, sodium salts |
Synonyms | SBE7-beta-CD sulfobutyl ether sodium salt BETADEX SULFOBUTYL ETHER SOIDUM betadex sulfobuytl ether sodium β-Cyclodextrin, sulfobutyl ethers Sodium sulfobutylether β-cyclodextrin Sulfobutylated beta-cyclodextrin sodium salt (DS~4) Sulfobutylated beta-cyclodextrin sodium salt (DS~6) beta.-Cyclodextrin, sulfobutyl ethers, sodium salts .beta.-Cyclodextrin, sulfobutyl ethers, sodium salts SBE-β-CD(Sulfobutyl Ether-β-cyclodextrin Sodium salt) |
CAS | 182410-00-0 194615-04-8 |
EINECS | 1308068-626-2 |
Molecular Formula | C42H70O35 |
Molar Mass | 1134.9842 |
Melting Point | 202-204°C (dec.) |
Solubility | Soluble in water. Insoluble in acetone, methanol, chloroform. |
Appearance | Solid powder |
Color | White to off white |
Storage Condition | Inert atmosphere,Room Temperature |
Use | SBE- β-CD is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. |
In vitro study | SBE-β-CD is a chemically modified β-CD that is a cyclic hydrophilic oligosaccharide which is negatively charged in aqueous media. β-CD functioned is a solubilizer only at low concentrations, whereas SBE7-β-CD exhibits strong solubilizing effects over a wide concentration range. |
In vivo study | 20% SBE-β-CD in saline: Guidelines (Following is our recommended protocol. This protocol only provides a guideline, and should be modified according to your specific needs). 1. Dissolve 0.9 g of NaCl in 100 mL distilled water to make a clear 0.9% saline solution. 2. Measure 2 g of dry SBE-β-CD. 3. Dissolve 2 g of SBE-β-CD in 0.9% saline to make 10 mL with a 20% (w/v) concentration. These may require ultrasonic (20-40 kHz, 30 seconds, repeat 3 times) or heating (37°C for about 30 minutes). If precipitation is observed, the precipitates can be dissolved by heating to 37°C and vortexing before use. |
HS Code | 2940006000 |
Reference Show more | 1. Zheng Xiaoxia, He Xiaohua, Huang Yanni et al. Pharmacokinetics of lansoprazole sodium enantiomers in dogs [J]. Chinese Pharmacist 2020(8). 2. Yang Peng, Lu Song, Wang Zhan, et al. Study on thermal stability and thermal decomposition kinetics of sulfobutyl-β-cyclodextrin [J]. Grain and Oil, 2018, 31(11):45-48. 3. Lu Lanfang, Yang Peng, Wang Zhan, et al. Phase solubility method to study the solubilization of cyclodextrin on kaempferol [J]. China Seasoning, 2019, 044(006):65-69. 4. Wu Chuanhong, Zhong Ruixue, Wei Tingsen, Wang Xiaoling. Preparation and Characterization of Inclusion Compound of Peppermint Oil-Sulfobutyl Ether-β-Cyclodextrin [J]. China Food Additives, 2020,31(09):14-18. 5. Yang Dan, Feng Liang, Liu Jun, Zhao Jing, Li Chao, Zhu Fagen, Shao Jianguo, Jia Xiaobin, Sun E. Study on Improvement of Drug Compliance of Pudilan Anti-inflammatory Oral Liquid for Children Based on Material Property Characterization Technology [J]. World Chinese Medicine, 2020,15(15):2221-2227. 6. Zheng Xiaoxia, He Xiaohua, Huang Yanni, Cheng Yanling. Pharmacokinetics of lansoprazole sodium enantiomers in dogs [J]. Chinese Pharmacist, 2020,23(08):1665-1668. 7. Liu Zhongbo. Construction of Food Grade Pickering Emulsion Based on Cyclodextrin [D]. Henan Institute of Science and Technology, 2021. 8. Han Dongxu, Li Tianle, Miao Ruidan, Wang Yao, Liu Liyan, Yu Zhan. Solubilization of seven-(2, 6-dimethyl)-β-cyclodextrin to luteolin [J]. Chinese modern applied pharmacy, 2020,37(22):2747-2751. 9. Xiao, Sirui, et al. "Increased microneedle-mediated transdermal delivery of tetramethylpyrazine to the brain, combined with borneol and iontophoresis, for MCAO prevention." International journal of pharmaceutics 575 (2020): 118962.https://doi.org/10.1016/j 10. [IF = 4.952] Fansheng Kong et al. "Inclusion complex of grape seeds extracts with sulfobutyl ether β-cyclodextrin: Preparation, characterization, stability and evaluation of α-glucosidase and α-amylase inhibitory effects in vitro." Lwt Food Sci Technol. 2019 Mar;101:819 11. [IF = 6.751] Ting Lei et al. "Rislenemdaz treatment in the lateral habenula improves despair-like behavior in mice." Neuropsychopharmacol. 2020 Mar;45(10):1717-1724 12. [IF = 5.875] Sirui Xiao et al. "Increased microneedle-mediated transdermal delivery of tetramethylpyrazine to the brain, combined with borneol and iontophoresis, for MCAO prevention." Int J Pharmaceut. 2020 Feb;575:118962 13. [IF = 2.72] Wenjin Zhu et al. "Development and physicochemical characterization of chitosan hydrochloride/sulfobutyl ether-β-cyclodextrin nanoparticles for cinnamaldehyde entrapment." J Food Biochem. 2020 Jun;44(6):e13197 |
use | sulfobutyl ether-β-cyclodextrin sodium is a new type of pharmaceutical preparation excipient, belonging to a sulfonic acid derivative of anionic highly water-soluble cyclodextrin. It can be well combined with drug molecules to form non-covalent complexes, which improves the stability, water solubility, and safety of the drug, and effectively improves the biological activity of the drug molecule. Its nephrotoxicity is small, and it can alleviate drug hemolysis., Control the rate of drug release. |
Preparation | Using β-cyclodextrin and 1,4-sulfobutyrolactone as raw materials, by introducing an appropriate amount of organic solvent into the alkaline aqueous solution, the solubility of 1,4-sulfobutyrolactone is increased, and the synthesis yield of sulfobutyl ether-β-cyclodextrin is improved; the obtained product solution is subjected to ultrasonic dialysis, activated carbon decolorization, freeze drying and other operations to obtain sulfobutyl ether-β-cyclodextrin powder products. |
biological activity | Captisol (SBE-β-CD, Sulfobutylether-β-Cyclodextrin) is a new type of chemically modified cyclodextrin with good stability and solubility. |